ABSCF (AB Science) Payments of Debt: $-2.24 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABSCF AB Science ABSCF
60 GF Score
Price $1.12
GF Value $1.39
Valuation Modestly Undervalued
! 11 Warning Signs
View Full Analysis

What is AB Science Payments of Debt?

AB Science ABSCF 60 Payments of Debt is $-2.24 Mil as of Dec. 2025. GuruFocus rates ABSCF with a GF Score™ of 60/100 and a GF Value™ of $1.39 (Modestly Undervalued). The stock has 11 warning signs investors should review.

AB Science's Payments of Debt for the six months ended in Dec. 2025 was $-1.89 Mil.

AB Science's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.24 Mil.

AB Science Payments of Debt Related Terms

AB Science Payments of Debt Historical Data

* Premium members only.

The historical data trend for AB Science's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AB Science Payments of Debt Chart

AB Science Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.87 -0.20 -1.31 -2.47 -2.25

AB Science Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.88 -0.90 -1.59 -0.35 -1.89
ABSCF
60GF Score
AB Science ABSCF
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AB Science Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-2.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-2.24 Mil mean?
AB Science (ABSCF) has a Payments of Debt of $-2.24 Mil as of Dec. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on AB Science and its competitors.
Is AB Science's Payments of Debt too high?
AB Science's current Payments of Debt is $-2.24 Mil. Overall, AB Science has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AB Science's Payments of Debt compare to ZTS and UTHR?
AB Science's Payments of Debt of $-2.24 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on AB Science and its competitors. AB Science's current Payments of Debt is $-2.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AB Science stock overvalued right now?
Based on GuruFocus' analysis, AB Science (ABSCF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.39, compared to a current price of $1.12 — trading 19.4% below its estimated fair value. The current Payments of Debt is $-2.24 Mil. AB Science's overall GF Score™ is 60/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For AB Science (ABSCF), the current Payments of Debt is $-2.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AB Science (ABSCF) Overvalued in 2026?

Based on GuruFocus' analysis, AB Science stock appears to be undervalued. The current stock price of $1.12 is trading 19.4% below its estimated GF Value™ of $1.39. GuruFocus considers AB Science to be Modestly Undervalued.

Key valuation signals for ABSCF:

  • Payments of Debt: $-2.24 Mil
  • GF Value™: $1.39 vs. price of $1.12 (19.4% below fair value)
  • GF Score™: 60/100 with 11 warning signs

No single metric tells the full story. See the ABSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AB Science Business Description

Other Exchanges 0Q77:UKAB:FranceA8D:Germany
Address 3, Avenue George V, Paris, FRA, 75008
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
60GF Score

Get the complete analysis for ABSCF

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.12
Price
$1.39
GF Value